Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Abstract

The aim of this study was to determine the prognostic value of expression of Excision Repair Cross-complementation Group 1 (ERCC1), B cell lymphoma/lewkmia-2 (Bcl-2) and metallothionein (MT) by immunohistochemically staining tumor specimens from 78 patients with advanced non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. The result showed that positive expression of ERCC1 was associated both with short survival (10.45 months vs. 14.38 months, log-rank p = 0.003) and poor response to cisplatin-based chemotherapy (p = 0.003) when compared with negative group. But expression of Bcl-2 and MT was not associated with response to chemotherapy and survival. Multivariate analysis confirmed that expression of ERCC1 was an independent variable related to overall survival (p = 0.013). These data support the role of RECC1 expression as a candidate predictor for the survival of patients with advanced NSCLC treated with cisplatin-based chemotherapy.